Are Peptides Legal in the EU?

Any peptide marketed for therapeutic use in the EU requires a marketing authorisation under Directive 2001/83/EC, but enforcement is handled by individual member states rather than the EMA centrally. This dual-level architecture – EU-wide legislation setting the rules, national agencies implementing them – means the same peptide compound can face materially different regulatory treatment in Germany versus Poland versus Spain, not because the law differs, but because enforcement intensity varies enormously.

Directive 2001/83/EC – The Community Code

The cornerstone of EU pharmaceutical regulation is Directive 2001/83/EC, formally the “Community code relating to medicinal products for human use.” Under Article 1(2) of this Directive, a medicinal product is any substance or combination of substances presented as having properties for treating or preventing disease in humans, or which may be administered to humans to restore, correct, or modify physiological functions. Peptides that are marketed, positioned, or sold for these purposes fall squarely within this definition and require a marketing authorisation (MA) before they can be legally placed on the market.

There are three authorisation routes. The centralised procedure, managed by the European Medicines Agency (EMA), grants a single MA valid across all 27 member states. This is mandatory for innovative biological medicines and orphan drugs, and optional for other products. Most major peptide drugs – semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro), liraglutide (Victoza/Saxenda), teriparatide (Forsteo) – hold centralised MAs. The decentralised procedure allows an applicant to seek simultaneous approval in multiple member states through a reference member state. The mutual recognition procedure extends an existing national MA to other member states.

In April 2026, the Court of Justice of the European Union (CJEU) delivered an important ruling in Case C-118/24 (EG Labo Laboratoires Eurogenerics v ANSM) that clarified the regulatory treatment of chemically synthesised peptides. The Court confirmed that a chemically synthesised peptide can be authorised as a generic of a biological reference product – provided it meets generic criteria including the same qualitative and quantitative composition in active substances, the same pharmaceutical form, and demonstrated bioequivalence. The case concerned teriparatide, where the reference product was manufactured biologically but the follow-on version was chemically synthesised. Germany served as the reference member state in the decentralised procedure. This ruling has commercial implications because the generic pathway involves less stringent regulatory requirements than the biosimilar pathway, potentially lowering the barrier for chemically synthesised peptide generics across the EU.

The bottom line: Under the EU’s Community Code, any peptide positioned for therapeutic use is a medicinal product requiring marketing authorisation – there is no “research use” carve-out at the EU level for products that imply human therapeutic benefit.

Regulation (EC) 726/2004 and the EMA

The EMA, headquartered in Amsterdam, is the EU’s centralised regulatory agency for medicines. It does not directly regulate research chemicals, issue enforcement actions against grey-market peptide vendors, or police individual consumers. Its role is to evaluate and supervise centrally authorised medicines and provide scientific advice. When it comes to unauthorized peptide products sold online, enforcement falls to national medicines agencies – the BfArM in Germany, the ANSM in France, the AEMPS in Spain, and so on.

This means the EMA does not maintain a list of banned or restricted peptides analogous to the FDA’s Category 2 list. There is no EU-wide positive list of peptides that compounding pharmacies may or may not prepare. Each member state handles compounding through its own national pharmaceutical law.

On 11 December 2025, the European Parliament and the Council of the EU reached political agreement on a comprehensive overhaul of EU pharmaceutical legislation – the most significant reform since Directive 2001/83/EC was adopted over 20 years ago. The final compromise texts were published in March 2026, with the new Directive and Regulation subject to formal adoption through 2026.

The new legislation replaces Directive 2001/83/EC and Regulation (EC) 726/2004 entirely. Key changes include a restructured data exclusivity period (from the current 8+2 model to a new 8+1 framework with conditional extensions), new “launch conditionality” mechanisms that penalise companies for delaying market entry in smaller member states, environmental sustainability requirements in manufacturing, and strengthened supply chain obligations to prevent medicine shortages. The Directive requires transposition into national law within approximately 36 months, meaning full implementation across all 27 member states is expected by roughly 2029.

For the peptide market specifically, the reform does not introduce new rules for research chemicals or change the fundamental framework for when a substance is classified as a medicinal product. However, it modernises the authorisation pathways and strengthens the regulatory infrastructure that governs how peptide medicines reach patients. The EMA’s new synthetic peptide manufacturing guideline (adopted December 2025, effective 1 June 2026) works alongside this reform – setting rigorous standards for process controls, impurity profiling, and lifecycle management of synthetic peptides intended as medicines.

The bottom line: The 2026 EU pharma reform replaces the legal framework that has governed peptide medicines since 2001, but it primarily affects pharmaceutical companies seeking marketing authorisations rather than the research peptide market directly.

Peptides sold as research chemicals – labelled “for research use only” and marketed without therapeutic claims – exist in a regulatory space that the EU framework does not specifically address at the supranational level. The EMA regulates medicinal products; research chemicals that do not claim to be medicinal products fall outside its direct scope.

In practice, this means that a company synthesising and selling BPC-157, TB-500, or CJC-1295 labelled as research compounds and marketed without health claims can operate legally in many EU jurisdictions – provided it complies with general chemical safety regulations, customs requirements, and does not trigger national pharmaceutical law by implying therapeutic use. However, the moment a vendor adds dosing guidance, before/after photographs, testimonials describing health outcomes, or language that positions the product as a treatment for any condition, the product risks reclassification as an unauthorized medicinal product under national law.

Enforcement intensity varies dramatically by member state. Western European nations with well-resourced pharmaceutical regulators – Germany, France, the Netherlands, Belgium – maintain stricter oversight. Eastern European countries, including Poland, Romania, and the Czech Republic, demonstrate more permissive attitudes toward research chemical sales, with fewer enforcement actions and less regulatory scrutiny of vendor marketing practices. This creates a practical reality where EU-based research peptide vendors often register in jurisdictions with lighter enforcement while shipping across the bloc via the EU’s internal market, which eliminates customs inspection for intra-EU shipments.

The most significant EU-level enforcement against illicit peptide and doping products is coordinated through Europol’s Operation SHIELD programme. The sixth iteration, Operation SHIELD VI, ran from April to November 2025 across 30 countries and produced striking results.

Metric	Result
Individuals prosecuted	3,354
Investigations launched	907
Organised crime groups investigated	43
Underground labs seized	5
Assembly/production sites seized	10
Websites taken down	66
Platforms monitored	233
Total value of seized items	EUR 33.17 million
Drug/doping units seized	Over 10 million
Participating countries	30 (incl. Germany, France, Greece, Italy, Spain)

Operation SHIELD VI specifically highlighted the “proliferation of counterfeit semaglutide-based products used as fat-burners” as a critical public health threat. The operation was supported by the European Anti-Fraud Office (OLAF), the EU Intellectual Property Office (EUIPO), Frontex, INTERPOL, and WADA. Participating EU member states included Germany, France, Italy, Spain, Greece, Belgium, the Netherlands, Austria, Finland, Denmark, and others.

The operation’s scope covered counterfeit and falsified medicines, trafficking of anabolic-androgenic steroids and other doping substances, illegal food supplements, and counterfeit medical devices. While it did not focus exclusively on peptides, peptide hormones, growth factors, and GLP-1 agonists fell squarely within its enforcement targets. In Germany specifically, investigators targeted groups reselling legally obtained prescription medicines via online shops and the darknet.

The bottom line: Operation SHIELD VI demonstrates that EU-level enforcement against the grey-market peptide and doping trade is coordinated, well-resourced, and intensifying – with over EUR 33 million in products seized in a single operation.

The EMA maintains a register of centrally authorised medicines that includes all major peptide drugs. The following peptide-based medicines hold valid EU marketing authorisations and are available through licensed pharmacies with a prescription.

Medicine	Active Peptide	Indication	Authorisation
Ozempic / Wegovy	Semaglutide	T2D / Obesity	Centralised (EMA)
Mounjaro	Tirzepatide	T2D / Obesity	Centralised (EMA)
Victoza / Saxenda	Liraglutide	T2D / Obesity	Centralised (EMA)
Forsteo	Teriparatide	Osteoporosis	Centralised (EMA)
Scenesse	Afamelanotide	EPP (light sensitivity)	Centralised (EMA)
Imcivree	Setmelanotide	Genetic obesity	Centralised (EMA)

Because enforcement is primarily national, the practical legality of research peptides varies across the EU. The following table provides a broad overview of how major member states approach the market.

Country	National Agency	Enforcement Level	Notes
Germany	BfArM	Strict	AMG + AntiDopG dual framework. See our Germany guide.
France	ANSM	Strict	Strong customs enforcement. Anti-doping law covers possession.
Netherlands	CBG-MEB	Moderate	Research peptide sales generally tolerated. Home to several EU-based suppliers.
Poland	URPL	Permissive	More permissive toward research chemical sales. Less enforcement activity.
Spain	AEMPS	Moderate	National anti-doping law applies to sporting context.
Italy	AIFA	Strict	Carabinieri Health Protection Command led SHIELD VI enforcement in Italy.
Czech Republic	SUKL	Permissive	Limited enforcement against research peptide vendors.

The practical consequence of this variation is significant. An EU-based research peptide vendor operating out of Poland or the Netherlands can ship to customers in Germany or France without triggering customs inspection, because intra-EU shipments are treated as internal market transfers with free movement of goods. The product crosses no external border and faces no customs scrutiny. By contrast, a shipment from the US or China to any EU member state must clear customs at the port of entry, where it is subject to inspection by national customs authorities and potential seizure if the product is classified as an unauthorized medicinal product or doping substance.

The bottom line: The EU’s internal market creates a regulatory arbitrage opportunity – vendors can base operations in permissive member states and ship freely to stricter ones without customs intervention.

Factor	EU	United States	Australia
Regulatory level	EU framework + national implementation	Federal (FDA)	Federal (TGA) + state penalties
Compound-specific list	No EU-level list	Category 1/2 system (phasing out)	SUSMP scheduling (S4/S8/S9)
Research peptide market	Tolerated (varies by country)	Increasingly restricted	Effectively prohibited
Anti-doping law	National (e.g. Germany’s AntiDopG)	WADA via USADA	WADA via ASADA
Regulatory direction (2026)	Stable (pharma reform focused on licensed medicines)	Loosening (reclassification)	Tightening (new scheduling)

For country-specific regulatory detail, see our guides to peptide legality in the US, peptide legality in the UK, and peptide legality in Australia. For Germany specifically, which has the EU’s most complex peptide regulatory landscape due to the dual AMG/AntiDopG framework, see our dedicated Germany guide.

The formal adoption and transposition of the new EU pharmaceutical Directive will be the defining regulatory event over the next three years. While the new framework primarily affects companies seeking marketing authorisations for peptide medicines, the modernised regulatory infrastructure may also tighten the enforcement environment for unauthorized products over time.

The EMA’s synthetic peptide manufacturing guideline (effective 1 June 2026) applies to pharmaceutical companies, not research chemical suppliers. However, it signals the EMA’s increasing focus on peptides as a pharmaceutical class and could influence how national agencies interpret the boundary between research chemicals and unauthorized medicines.

The counterfeit semaglutide problem highlighted by Operation SHIELD VI is likely to drive further enforcement. As GLP-1 demand continues to outstrip supply in several EU markets, the incentive for unauthorized production and distribution grows – and with it, the regulatory response.